uvaretin: chloroform extract of Uvaria acuminata Oliv.; structure
uvaretin : A member of the class of dihydrochalcones that is 1,3-diphenylpropan-1-one in which the phenyl group that is bonded to the carbonyl group is substituted by hydroxy groups at positions 2 and 4, an o-hydroxybenzyl group at position 3, and a methoxy group at position 6. A cytotoxic natural product found particularly in Uvaria acuminata and Uvaria chamae.
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Uvaria | genus | A plant genus of the family ANNONACEAE. Members contain uvarigrin, uvarigrandin, chamuvaritin and other acetogenins and benzylisoquinoline alkaloids.[MeSH] | Annonaceae | The custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH] |
Uvaria acuminata | species | [no description available] | Annonaceae | The custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 73447 |
CHEMBL ID | 523296 |
CHEBI ID | 9915 |
SCHEMBL ID | 4743874 |
MeSH ID | M0058859 |
Synonym |
---|
NSC241906 , |
1-propanone,4-dihydroxy-3-[(2-hydroxyphenyl)methyl]-6-methoxyphenyl]-3-phenyl- |
nsc-241906 |
NCIMECH_000569 |
NCI60_001940 |
NCGC00180537-01 |
58449-06-2 |
uvaretin |
C09978 |
MEGXP0_001394 |
ACON1_001408 |
LMPK12120469 |
BRD-K57086287-001-01-8 |
1-(2,4-dihydroxy-3-(2-hydroxybenzyl)-6-methoxyphenyl)-3-phenyl-1-propanone |
1-[2,4-dihydroxy-3-[(2-hydroxyphenyl)methyl]-6-methoxyphenyl]-3-phenylpropan-1-one |
CHEMBL523296 |
chebi:9915 , |
CCG-35562 |
nsc 241906 |
unii-vz5c9ul7v1 |
1-(2,4-dihydroxy-3-((2-hydroxyphenyl)methyl)-6-methoxyphenyl)-3-phenyl-1-propanone |
vz5c9ul7v1 , |
SCHEMBL4743874 |
1-[2,4-dihydroxy-3-(2-hydroxybenzyl)-6-methoxyphenyl]-3-phenylpropan-1-one |
DTXSID50207148 |
Q27089383 |
1-propanone, 1-(2,4-dihydroxy-3-((2-hydroxyphenyl)methyl)-6-methoxyphenyl)-3-phenyl- |
HY-N10129 |
1-[2,4-dihydroxy-3-[(2-hydroxyphenyl)methyl]-6-methoxyphenyl]-3-phenyl-1-propanone |
CS-0310817 |
AKOS040758209 |
Role | Description |
---|---|
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
resorcinol | A benzenediol that is benzene dihydroxylated at positions 1 and 3. |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
dihydrochalcones | Any ketone that is 1,3-diphenylpropanone and its derivatives obtained by substitution. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1537699 | Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs in presence of doxorubicin by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1647668 | Antibacterial activity against Escherichia coli at 5 mM incubated for 18 hrs by AlamarBlue assay | |||
AID402115 | Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine uptake | 1998 | Journal of natural products, Sep, Volume: 61, Issue:9 | Antimalarial principles from Artemisia indica. |
AID1647669 | Antibacterial activity against Bacillus subtilis incubated for 18 hrs by AlamarBlue assay | |||
AID1537671 | Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537670 | Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537672 | Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537700 | Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs in presence of 6TP by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537673 | Cytotoxicity against human REH cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537702 | Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs in presence of etoposide by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID381255 | Cytotoxicity against mouse P388 cells relative to control | |||
AID1877819 | Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as reduction in cell survival at 10 uM | 2022 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 58 | Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation. |
AID1537674 | Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1537669 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | The winding road of the uvaretin class of natural products: from total synthesis to bioactive agent discovery. |
AID1647670 | Cytotoxicity against human MCF7 cells after 24 hrs by PrestoBlue cell viability reagent based assay | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 3 (42.86) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.83) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |